Increasing Productivity of Mammalian Cells
CHO Plus has developed engineered mammalian cells with higher specific productivity. Our associated screening technology will yield more high-producing cells while screening fewer clones.
Technology Breakthrough
Using patented methods for creating genetically-engineered cells, CHO Plus has created (CHO) cells capable of up to 10-fold higher protein productivity in model systems (13.5 g/l mAb in shake flasks; 117 pg/cell/day). We have also created (HEK-293) cells capable of over 15-fold AAV productivity improvement, with up to 55% full capsids; and developed a stably-transfected, inducible AAV packaging cell line.
These technologies will lower production costs, significantly reduce the amount of culture medium required, and reduce the need to build many expensive manufacturing facilities. We are currently demonstrating commercial feasibility via production of human monoclonal antibodies using engineered CHO cells, and via production of viral vectors (AAV) using engineered HEK-293 cells. See our recent poster presentations below.
Advancing Manufacture of CGT 2024
%20-%20thumbnail.png)
Cell Culture Engineering 2023 (Platform)
%20-%20thumbnail.png)
Cell Culture Engineering 2023 (Antibodies)
%20-%20thumbnail.png)
Cell Culture Engineering 2023 (AAV)
Higher-Productivity Manufacturing Processes
CHO Plus engineered cells currently in commercial feasibility testing could be introduced into existing manufacturing processes and infrastructure. This will dramatically increase production capacity and plant flexibility for existing facilities, and will limit the need for constructing new facilities. Licensing and royalty costs will match accepted industry standards, while providing cell lines with higher productivity.